ATE214924T1 - Verwendung von nebivolol als anti-atherogenisches mittel - Google Patents

Verwendung von nebivolol als anti-atherogenisches mittel

Info

Publication number
ATE214924T1
ATE214924T1 AT95942209T AT95942209T ATE214924T1 AT E214924 T1 ATE214924 T1 AT E214924T1 AT 95942209 T AT95942209 T AT 95942209T AT 95942209 T AT95942209 T AT 95942209T AT E214924 T1 ATE214924 T1 AT E214924T1
Authority
AT
Austria
Prior art keywords
atherogeneic
nebivolol
agent
alpha
chromanmethanol
Prior art date
Application number
AT95942209T
Other languages
English (en)
Inventor
Anne Simone Josephine Lesage
Josepha Eduarda Maria F Leysen
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE214924T1 publication Critical patent/ATE214924T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyrane Compounds (AREA)
AT95942209T 1994-12-28 1995-12-21 Verwendung von nebivolol als anti-atherogenisches mittel ATE214924T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94203775 1994-12-28
PCT/EP1995/005174 WO1996019987A1 (en) 1994-12-28 1995-12-21 Use of nebivolol as an anti-atherogenic

Publications (1)

Publication Number Publication Date
ATE214924T1 true ATE214924T1 (de) 2002-04-15

Family

ID=8217503

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95942209T ATE214924T1 (de) 1994-12-28 1995-12-21 Verwendung von nebivolol als anti-atherogenisches mittel

Country Status (20)

Country Link
US (2) US5874461A (de)
EP (1) EP0801564B1 (de)
JP (1) JPH10511655A (de)
KR (1) KR100264348B1 (de)
CN (1) CN1167418C (de)
AT (1) ATE214924T1 (de)
AU (1) AU700364B2 (de)
CA (1) CA2207333C (de)
CZ (1) CZ287513B6 (de)
DE (1) DE69526120T2 (de)
DK (1) DK0801564T3 (de)
ES (1) ES2176354T3 (de)
FI (1) FI118884B (de)
HU (1) HU226208B1 (de)
NO (1) NO315687B1 (de)
NZ (1) NZ298074A (de)
PT (1) PT801564E (de)
SI (1) SI0801564T1 (de)
SK (1) SK282144B6 (de)
WO (1) WO1996019987A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0801564B1 (de) * 1994-12-28 2002-03-27 Janssen Pharmaceutica N.V. Verwendung von nebivolol als anti-atherogenisches mittel
DE19716120A1 (de) * 1997-04-17 1998-10-22 Europ Lab Molekularbiolog Verwendung von cholesterinsenkenden Mitteln
US6713651B1 (en) 1999-06-07 2004-03-30 Theravance, Inc. β2-adrenergic receptor agonists
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
JP2000207219A (ja) * 1999-01-18 2000-07-28 Fujitsu Ten Ltd 車載端末とセンタ―との間の通信システム、及び、通信システムに使用する車載端末
US6683115B2 (en) 1999-06-02 2004-01-27 Theravance, Inc. β2-adrenergic receptor agonists
US6593497B1 (en) 1999-06-02 2003-07-15 Theravance, Inc. β2-adrenergic receptor agonists
UA73965C2 (en) 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
DK1355644T3 (da) 2001-01-26 2006-10-23 Schering Corp Anvendelse af substituerede azetidinonforbindelser til behandling af sitosterolæmi
HU230253B1 (hu) 2001-01-26 2015-11-30 Merck Sharp & Dohme Corp Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére
WO2002087508A2 (en) * 2001-05-02 2002-11-07 Nitromed, Inc. Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
JP2005504091A (ja) 2001-09-21 2005-02-10 シェーリング　コーポレイション ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
AU2003287250B9 (en) * 2002-10-30 2010-01-28 Ptc Therapeutics, Inc. Identifying therapeutic compounds based on their physical-chemical properties
WO2004043457A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
CA2517571C (en) 2003-03-07 2011-07-05 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP4589919B2 (ja) 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
JP2006519869A (ja) 2003-03-07 2006-08-31 シェーリング　コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
ITTO20030140U1 (it) * 2003-09-16 2005-03-17 Interfila Srl Matita cosmetica
WO2005033093A1 (en) 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. 7,8-bicycloalkyl-chroman derivatives
US7838552B2 (en) 2004-06-04 2010-11-23 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US7803838B2 (en) 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
EP1741712B1 (de) 2004-07-30 2011-06-15 Torrent Pharmaceuticals Ltd amorphes nebivolol hydrochlorid und seine Herstellung
JP2008528626A (ja) * 2005-01-31 2008-07-31 マイラン ラボラトリーズ インク． ヒドロキシル化されたネビボロールを含む薬学的組成物
ES2619303T3 (es) 2005-06-01 2017-06-26 Edison Pharmaceuticals, Inc. Productos terapéuticos redox activos para el tratamiento de enfermedades mitocondriales y otras afecciones y modulación de biomarcadores energéticos
WO2007100652A2 (en) 2006-02-22 2007-09-07 Edison Pharmaceuticals, Inc. Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
EA038941B1 (ru) 2007-11-06 2021-11-12 ПиТиСи ТЕРАПЬЮТИКС, ИНК. ПРОИЗВОДНЫЕ 4-(п-ХИНОНИЛ)-2-ГИДРОКСИБУТАНАМИДА ДЛЯ ЛЕЧЕНИЯ МИТОХОНДРИАЛЬНЫХ ЗАБОЛЕВАНИЙ
WO2009091777A1 (en) * 2008-01-15 2009-07-23 Forest Laboratories Holdings Limited Nebivolol in the treatment of sexual dysfunction
WO2009111576A2 (en) 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc. 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
MX363223B (es) 2008-09-10 2019-03-15 Bioelectron Tech Corp Tratamiento de trastornos generalizados del desarrollo con terapeuticos con actividad redox.
EP2362726B1 (de) 2008-10-14 2018-08-08 Bioelectron Technology Corporation Behandlung von oxidationsstresserkrankungen, darunter kontrast-nephropathie, strahlungsschädigung und störungen der hämatozytenfunktion
EP2379710A1 (de) * 2008-12-19 2011-10-26 Schering Corporation Futterzusatz für die säugerzellkultur und verwendungsverfahren
CA2777479C (en) 2009-04-28 2017-10-17 Ptc Therapeutics, Inc. Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
HK1161509A2 (en) * 2010-06-04 2012-07-27 全球药物科技有限公司 Oral meclizine aqueous formulations with taste flavoring agent
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
DE102014107132A1 (de) 2014-05-20 2015-11-26 Corden Pharma International Gmbh Verfahren zur Herstellung von Epoxiden die in der Herstellung von Nebivolol und dessen Derivaten einsetzbar sind
US20170304286A1 (en) * 2014-10-24 2017-10-26 Launx Biomedical Co., Ltd. New indication of paroxetine pharmaceutical composition for treating cancer
DK3233786T3 (da) 2014-12-16 2022-05-09 Ptc Therapeutics Inc Polymorfe og amorfe former af (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6- dioxocyclohexa-1,4-dienyl)butanamid
US10703701B2 (en) 2015-12-17 2020-07-07 Ptc Therapeutics, Inc. Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1337432C (en) * 1988-03-23 1995-10-24 Raymond M. Xhonneux Method of lowering the blood pressure
TW355683B (en) * 1994-02-17 1999-04-11 Janssen Pharmaceutica Nv Composition containing micronized nebivolol
EP0801564B1 (de) * 1994-12-28 2002-03-27 Janssen Pharmaceutica N.V. Verwendung von nebivolol als anti-atherogenisches mittel

Also Published As

Publication number Publication date
US5874461A (en) 1999-02-23
HU226208B1 (en) 2008-06-30
SK282144B6 (sk) 2001-11-06
CN1171739A (zh) 1998-01-28
DE69526120D1 (de) 2002-05-02
NZ298074A (en) 2001-01-26
NO972980D0 (no) 1997-06-26
DK0801564T3 (da) 2002-07-15
PT801564E (pt) 2002-09-30
HUT77927A (hu) 1998-11-30
FI118884B (fi) 2008-04-30
CA2207333C (en) 2006-10-17
EP0801564A1 (de) 1997-10-22
SK85697A3 (en) 2000-04-10
CN1167418C (zh) 2004-09-22
AU4347796A (en) 1996-07-19
CA2207333A1 (en) 1996-07-04
WO1996019987A1 (en) 1996-07-04
FI972793L (fi) 1997-06-27
ES2176354T3 (es) 2002-12-01
NO315687B1 (no) 2003-10-13
AU700364B2 (en) 1999-01-07
SI0801564T1 (en) 2002-08-31
JPH10511655A (ja) 1998-11-10
EP0801564B1 (de) 2002-03-27
MX9704669A (es) 1997-09-30
NO972980L (no) 1997-06-26
US6075046A (en) 2000-06-13
CZ191997A3 (cs) 1999-01-13
FI972793A0 (fi) 1997-06-27
DE69526120T2 (de) 2002-11-28
CZ287513B6 (en) 2000-12-13
KR100264348B1 (ko) 2000-08-16

Similar Documents

Publication Publication Date Title
ATE214924T1 (de) Verwendung von nebivolol als anti-atherogenisches mittel
TR199901174T2 (xx) Yeni heterosiklilmetil-ikameli pirazol t�revleri.
TR199901172T2 (xx) Yeni ikame edilmi� pirazol t�revleri.
DE69920757D1 (de) Immunsuppressive wirkungen von pteridinderivaten
IL130931A0 (en) Small molecules useful in the treatment of inflammatory disease
HUP9700603A1 (hu) Gyógyászati készítmény véralvadási zavarok kezelésére
DE69725879D1 (de) VERWENDUNG VON p-AMINOPHENOLDERIVATEN ZUR HERSTELLUNG VON PHARMAZEUTISCHEN ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN
ATE528279T1 (de) 3-butenyl-1-aminederivate und ihre verwendung als ih modulatoren von therapie für psychiatrische erkrankungen
ATE151774T1 (de) Cyclopentanperhydrophenanthren-17-beta-(3-furyl - 3-derivate und pharmazeutische präparate davon, zur behandlung von kardiovaskulär-erkrankungen
TR199901385T2 (xx) Piperidin t�revleri.
ATE113591T1 (de) 4-benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol- - one und ihre verwendung als antikonvulsiva.
ATE246924T1 (de) Neue therapeutische verwendung von nicergoline
NO984651D0 (no) Anvendelse av benzonaftalenderivater for fremstilling av medikamenter for behandling av sykdommer i sentralnervesystemet
DE59708511D1 (de) Verwendung von 7-(1-aminomethyl-2-oxa-7-aza-bicyclo 3.3.0]oct-7-yl)-chinoloncarbonsäure- und -naphthyridoncarbonsäure-derivaten zur therapie von helicobacter-pylori-infektionen und den damit assoziierten gastroduodenalen erkrankungen
AU1569700A (en) Novel therapeutic application of low molecular weight heparin
ATE225181T1 (de) Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen
TR200003352T2 (tr) Yeni pentaerythrit türevleri, bunların imalatı ve kullanımları ile bunların sentezi için ara maddeler
FI972673A7 (fi) 4,4-(disubstituoitu)sykloheksan-1-oli-monomeereja ja vastaavia yhdiste itä
DK0820308T3 (da) Konjugat til behandling af inflammatoriske sygdomme
NO984198D0 (no) Fremgangsmåte for behandling av aggresjon
AU1278700A (en) Novel therapeutic use of 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergoline
MX9706454A (es) Uso de benzotiazoles fusionados como neuroproyectores.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification